Omar Nadeem, MD

Articles

Quadruplet Therapy in Transplant-Eligible NDMM: Implications of GRIFFIN and MASTER Studies

June 29th 2022

Shared insight on clinical trial results from both the GRIFFIN and MASTER trials, and the key role of frontline quadruplet regimens in transplant-eligible NDMM.

Evaluating Frontline Treatment Strategies in NDMM: The DETERMINATION Trial

June 29th 2022

Expert hematologist-oncologists open their discussion on NDMM management by reviewing frontline data from the recent DETERMINATION trial.

Precursor Conditions Unlock Potential for Early Interventions in Multiple Myeloma

March 29th 2022

Data presented at the ASH Annual Meeting and Exposition underscored the growing focus on improving screening, advancing methods of detection, and improving our understanding of the genomic, genetic, and epigenetic factors that govern progression and therapeutic resistance in multiple myeloma.

Dr. Nadeem on the Uptake of Novel Therapies in Heavily Pretreated Multiple Myeloma

July 15th 2021

Omar Nadeem, MD, discusses the uptake of novel therapies in heavily pretreated multiple myeloma.

Dr. Nadeem on the Integration of Isatuximab in Relapsed/Refractory Multiple Myeloma

June 29th 2021

Omar Nadeem, MD, discusses the integration of isatuximab-irfc in relapsed/refractory multiple myeloma.

Dr. Nadeem on the Emergence of Quadruplet Regimens in Multiple Myeloma

June 21st 2021

Omar Nadeem, MD, discusses the emergence of quadruplet regimens in multiple myeloma.

Dr. Nadeem on Individualizing Therapy in Multiple Myeloma

July 25th 2019

Omar Nadeem, MD, a physician at Dana-Farber Cancer Institute and an instructor in medicine at Harvard Medical School, discusses individualizing therapy for patients with multiple myeloma.

Dr. Nadeem on Sequencing Considerations in Multiple Myeloma

April 29th 2019

Omar Nadeem, MD, a physician at Dana-Farber Cancer Institute and an instructor in medicine at Harvard Medical School, discusses sequencing challenges in multiple myeloma.